104 related articles for article (PubMed ID: 2851181)
1. Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy.
Williams CJ; Woods R; Levi J; Page J
Semin Oncol; 1988 Dec; 15(6 Suppl 7):58-61. PubMed ID: 2851181
[TBL] [Abstract][Full Text] [Related]
2. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
Woods RL; Williams CJ; Levi J; Page J; Bell D; Byrne M; Kerestes ZL
Br J Cancer; 1990 Apr; 61(4):608-11. PubMed ID: 1691921
[TBL] [Abstract][Full Text] [Related]
3. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
Kubota K; Watanabe K; Kunitoh H; Noda K; Ichinose Y; Katakami N; Sugiura T; Kawahara M; Yokoyama A; Yokota S; Yoneda S; Matsui K; Kudo S; Shibuya M; Isobe T; Segawa Y; Nishiwaki Y; Ohashi Y; Niitani H;
J Clin Oncol; 2004 Jan; 22(2):254-61. PubMed ID: 14722033
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
8. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tominaga K; Sakurai M; Suga J; Miyaoka H; Sano T; Keicho N
Jpn J Cancer Res; 1986 Aug; 77(8):782-9. PubMed ID: 3019976
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
[TBL] [Abstract][Full Text] [Related]
11. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
Einhorn LH; Loehrer PJ; Williams SD; Meyers S; Gabrys T; Nattan SR; Woodburn R; Drasga R; Songer J; Fisher W
J Clin Oncol; 1986 Jul; 4(7):1037-43. PubMed ID: 3088219
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing vindesine and cisplatinum to vindesine and methotrexate in advanced non small cell lung carcinoma.
Harvey VJ; Slevin ML; Cheek SP; Barnett MJ; Gregory W; Thompson JP; Wrigley PF
Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1615-9. PubMed ID: 2828071
[TBL] [Abstract][Full Text] [Related]
13. [A randomized trial comparing vindesine plus cisplatin with mitomycin C, vindesine plus cisplatin in patients with advanced non-small cell lung cancer].
Fujii M; Kiura K; Okabe K; Toki H; Kimura M
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2676-81. PubMed ID: 2820312
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.
Saito H; Shimokata K; Saka H; Yamamoto M; Ogasawara T; Nomura F; Sakai S; Iwata M; Murate T; Miyachi T
Cancer Chemother Pharmacol; 1993; 33(2):154-6. PubMed ID: 8261575
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G; Splinter TA; Debruyne C; Kho GS; Lianes P; van Zandwijk N; Pennucci MC; Scagliotti G; van Meerbeeck J; van Hoesel Q; Curran D; Sahmoud T; Postmus PE
J Clin Oncol; 1998 Jun; 16(6):2133-41. PubMed ID: 9626213
[TBL] [Abstract][Full Text] [Related]
19. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
